Form 4: Director Melinda Brown Exercises Precision BioSciences RSUs

Director Melinda Brown acquired 21,000 shares of Precision BioSciences common stock through the vesting of restricted stock units.

Summary

• Director Melinda Brown exercised 21,000 restricted stock units (RSUs) on May 20, 2026.
• The RSUs converted into 21,000 shares of common stock at no additional cost.
• Following the transaction, the reporting person holds a total of 44,346 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard administrative vesting of director compensation rather than a market-moving signal.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified.

Risks

• Continued service requirements for future equity vesting.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a routine disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting for directors is standard practice in the biotechnology sector to ensure long-term alignment between board members and corporate performance.

Comparison to Industry Standards

• The transaction follows standard equity compensation structures common among mid-cap and small-cap biotech firms.
• The vesting schedule is consistent with typical annual director compensation cycles.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Precision BioSciences, DTIL, Form 4, Insider Trading, Restricted Stock Units, Biotech